The analysis of the available data from the MILE study group also showed a heterogeneous expression profile, with MLL2/KMT2D and MLL3/KMT2C upregulated in the pool of CML patients. This evidence concerns the gene KMT2D and chronic myelogenous leukemia, BCR-ABL1 positive.